Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice

The endocannabinoid system is involved in various factors relevant to alcohol and drug abuse (Parsons and Hurd, 2015; Volkow et al., 2017; Zlebnik and Cheer, 2016). In particular, the selective CB1R antagonist / inverse agonist rimonabant (formerly SR141716  A) decreases alcohol consumption in animals, possibly by indirect modulation of dopaminergic neurotransmission (Arnone et al., 1997; Vasiljevik et al., 2013; Vinod et al., 2008). In addition, activating CB2Rs modulates the reinforcing effects of ethanol (Ishiguro et al., 2007) and protects agains t alcohol-induced liver disease (Louvet et al., 2011) in mice.
Source: Drug and Alcohol Dependence - Category: Addiction Authors: Tags: Full length article Source Type: research